课题基金 / 基金详情

SAFETY, TOLERANCE & PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)

SAFETY, TOLERANCE & PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)
安全、宽容
批准号：
6586823
负责人：
S. Gail Eckhardt
金额：
$23.48万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
项目状态：
已结题
起止时间：
2001-12-01 至 2002-11-30
来源：
https://reporter.nih.gov/project-details/6586823
关键词：
antineoplastics cholestane compound clinical research clinical trial phase I dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy neoplastic process pharmacokinetics

项目摘要

项目成果

S. Gail Eckhardt的其他基金

相关文献

中文摘要
翻译
研究药物乳酸角鲨胺通过抑制肿瘤血液供应的发展来抑制实体瘤的生长，而对肿瘤细胞没有直接的细胞毒性。 它以前没有在人类受试者中进行过测试。 本研究的目的是确定最大耐受剂量，确定定性和定量毒性特征，确定连续5天输注的推荐剂量，并表征药物的药代动力学和药效学特征。
英文摘要
The study drug, squalamine lactate, inhibits growth of solid tumors by inhibiting the development of a blood supply to the tumor without direct cytotoxicity to tumor cells. It has not been previously tested in human subjects. The purposes of this study are to determine the maximum tolerated dosage, determine the qualitative and quantitative toxicity charcteristics, determine the recommended dose as a continuous five day infusion, and characterize the pharmacokinetic and pharmacodynamic charcteristcs of the drug.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium